Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reactive and therapy induced bone marrow changes linked to systemic infectious and non-infectious disorders including MAS/HLH report from the European association for haematopathology, Dubrovnik 2024.

Virchows Archiv : an international journal of pathology·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Haematologica·2026
Same author

A subset of histamine H4 receptor antagonists prevents B lymphocyte proliferation induced by BCR/TLR9 engagement or EBV infection.

Antiviral research·2026
Same author

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

The American journal of surgical pathology·2026
Same author

Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.

Blood advances·2026

Related Experiment Video

Updated: May 23, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Splenic marginal zone lymphoma: current knowledge and future directions.

Catherine Thieblemont1, Frederic Davi, Maria-Elena Noguera

  • 1Hôpital Saint-Louis, Paris, France. catherine.thieblemont@sls.aphp.fr

Oncology (Williston Park, N.Y.)
|April 12, 2012
PubMed
Summary

Splenic marginal zone lymphoma (SMZL) is an indolent lymphoma often presenting with splenomegaly and autoimmune issues. Diagnosis can be challenging, but recent advances improve characterization and treatment strategies.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Splenic marginal zone lymphoma (SMZL) originates from the marginal zone, similar to MALT and nodal marginal zone lymphomas.
  • Despite a common origin, SMZL exhibits distinct clinical and probable biological variations.
  • Recent research has elucidated pathogenic mechanisms and therapeutic advancements for SMZL.

Purpose of the Study:

  • To review current knowledge on the biological findings of SMZL.
  • To detail the clinical features and diagnostic challenges of SMZL.
  • To summarize therapeutic approaches and highlight areas lacking treatment consensus.

Main Methods:

  • Literature review of recent findings on SMZL.
  • Analysis of clinical characteristics, including presentation and diagnosis.
  • Evaluation of current therapeutic strategies and their efficacy.

Main Results:

  • SMZL is typically an indolent, disseminated disease at diagnosis, characterized by splenomegaly and frequent autoimmune manifestations.
  • Diagnostic differentiation from other low-grade lymphomas remains a challenge, though improved criteria are emerging.
  • Treatment options include splenectomy or immunochemotherapy, with no universal consensus except for hepatitis C virus-associated cases.

Conclusions:

  • SMZL requires careful diagnosis due to its complexity and overlap with other lymphomas.
  • Understanding biological variations is key to refining treatment strategies.
  • Further research is needed to establish optimal therapeutic guidelines for SMZL.